Announcing the Global Partnering Campaign, LSN’s Newest Product

10 Aug

By Karen Deyo, Director of Product, Israel BD, LSN

Life Science Nation (LSN) is excited to announce that our newest product, the Global Partnering Campaign Salesforce App, is live! This is a new way to access the LSN Investor and Licensing Partner Database, taking the benefits of LSN’s curated data (10 categories of investors from 3,000 firms with 10,000 contacts), and combining it with LSN’s custom-developed fundraising campaign management tool.

What is the difference between the LSN Investor and Licensing Partner Database and the new GPC product?

The GPC product is a Salesforce App that has to be downloaded off of the Salesforce AppExchange and installed into the company’s Salesforce account. The LSN Investor and Licensing Partner Database gives you access to the same content without a subscription to Salesforce.

Do I need to subscribe to Salesforce to use the new GPC product?

Yes, this new product is available through Salesforce only. Using a CRM like Salesforce is a crucial tool for managing a fundraising campaign and tracking all of your contact with investors and licensing partners – ensuring no missed opportunities or dropped balls.

What do I need to do to get the GPC App?

If you are not already a Salesforce client, subscribe to Salesforce (Professional license or above required), go the Salesforce AppExchange, and find and install the Life Science Nation – Global Partnering Campaign (GPC) app. Once you have installed the app, you will need to subscribe to the Essential or Premium plan through this link and contact LSN at gpc@lifesciencenation.com for your onboarding with your BD representative. After the onboarding is complete, LSN staff will activate the GPC app, and you can start identifying your Global Target List of investors and licensing partners and begin your outreach!

Click here to watch a demo of the new product!

RESI-Boston-2023-September-1100px-w

Interview with Shikha Sharma, Senior Director, Innovation at California Life Sciences (CLS)

10 Aug
Shikha-SharmaShikha Sharma Interview with Shikha Sharma, Senior Director, Innovation at California Life Sciences

By Caitlin Dolegowski, Marketing Manager, LSN

 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): Please introduce us to California Life Sciences.

Shikha Sharma (SS): California Life Sciences (CLS) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, CLS has served the community by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. On behalf of our more than 1,200 member organizations, CLS works to shape public policy, improve access to breakthrough technologies, educate lawmakers, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. In doing so, CLS fulfills its mission to protect and nurture California’s life sciences industry, empowering discoveries that lead to healthier lives around the world.

CD: What type of companies do California Life Sciences consider for membership?

SS: CLS members represent companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector.

CD: What stage of fundraising is California Life Sciences looking to support?

SS: The CLS Innovation & Entrepreneurship programs primarily support early-stage companies in fundraising stages from pre-seed to Series A. However, the broader CLS community encompasses members, companies, stakeholders, and pharma industry professionals with accessibility to later stage fundraising know-how and connections. Becoming part of CLS gives you access to a broad network that can directly and indirectly support companies in any stage of fundraising.

CD: Clearly, California Life Sciences, is in California. Though, not all your members are located in California. What are your geographic qualifications?

SS: We don’t have geographic qualifications, per se.  CLS welcomes any organization that is looking to access, expand and/or maintain a foothold in what I would consider the most robust life sciences ecosystem worldwide.

CD: What works well for California Life Sciences in being a part of the RESI experience?

SS: As part of our portfolio of entrepreneurship services, CLS seeks to establish partnerships with respected partnering and investor conferences to aid our members in the fundraising journeys. Importantly, opportunities like RESI connects them with Seed and Series B investors, channel and licensing partners.

CD: What other information is important for companies to consider about California Life Sciences?

SS:  California Life Sciences’ innovation and entrepreneurship initiatives connect life science startups to the resources needed to help them effectively scale their ventures. Our programs create a platform for accessing business partners, investors, foundations and patient advocacy organizations, peers, and other industry leaders.

Designed to nurture and advocate for emerging and diverse innovators from throughout the state, CLS offers advisory services, positioning for capital tools, access to capital through strategic partnerships and events and US market access resources to help in the development and commercialization of their business.

RESI-Boston-2023-September-1100px-w

Hot Investor Mandate: USA-Based Multi Family Office Invests in Seed to Series A Life Science Companies, With Strong Interests in Oncology

10 Aug

A USA-based multi-family office invests across several sectors, with a focus on life science and healthcare. The firm typically seek opportunities in Seed to Series A rounds, with an initial check size ranging from $500K to $3M USD. Within life science and healthcare, approximately half the firm’s investments have been in companies related to oncology, which is an area of special interest to the firm. While most of their investments have been in the US, the firm will consider opportunities in other countries like Canada and Europe. The firm is typically a co-investor.

Within life science and healthcare, the firm is interested in biotech therapeutics, medtech, and is open to diagnostics and life science tools as well. The firm is agnostic to subsectors, although cell and gene therapy is one area of interest. The firm is open to considering companies at an early stage of development, from pre-clinical to phase I for therapeutics and from in-development to clinical stage for medical devices. The firm is open to devices across all classes. For indications, oncology stands out as a particular area of interest for the firm.

While the firm does not have special requirements regarding the founding or management team. The firm does place emphasis on partnering with experienced founders and value the expertise and track record of the founder.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm With US & Europe Offices Invests With a New Fund in Early-Stage Life Sciences With Opportunistic Mandate

10 Aug

A venture capital firm newly founded in 2023 and dually headquartered in the U.S. and Europe  is looking to invest from its new fund in life science startups typically in the Series A round. Typical check size is flexible but ranges from $250k-2M. The firm is looking to invest in companies from the U.S., Europe, Israel, and the Middle East. The firm’s co-founder is NIH trained and has done consulting with the FDA, bringing their expertise to investments and companies.

The firm is investing in life science sectors including: 50% in therapeutics, 20% in medical devices, 20% in diagnostics, and 10% in health-tech. The firm is open to all modalities and technologies. In terms of therapeutics, the firm prefers companies that are Pre-Clinical up to Phase II and will not look farther than that. The firm is indication-agnostic and is open to looking at orphan diseases.

The firm may take a board seat on a case-by-case basis but does not have specific management team requirements. The firm can participate as a lead investor or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based Global Pharmaceutical Seeks Innovative Drug Candidates for Strategic Partnership in Oncology, CNS, Autoimmune Disease, and More

10 Aug

One of the leading fully integrated biopharmaceutical companies in China with multiple integrated R&D centers in US and China is actively seeking licensing/collaboration on development candidates with first-in-class or best-in-class potentials and commercial products with substantial market opportunities in China and worldwide.

The firm is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease.

The firm is looking for companies with capacity and experience to implement R&D plans. The firm is interested in incubating companies from scratch.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Fund Seeks New Opportunities in Digital Health, Software, and Tech-Enabled Healthcare Services

10 Aug

A venture capital fund based in the US looks to make initial equity investments ranging anywhere from $750,000 and up, with most investments falling in the $2-3M million range for the life of the investment. The firm is actively seeking new investments in the US.

The firm is interested in healthcare software companies and tech-enabled healthcare services, with a deep interest in software platforms for clinical trials and pharma services. The firm is interested in B2B SaaS business models and those that have some initial customer traction. The firm is not interested in therapeutics, medical devices, or diagnostics.

The firm does not look to take controlling investments in companies. They take a board seat following investment. The firm is interested in privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Apply before August 9 and Join these Confirmed Companies at RESI September Innovator’s Pitch Challenge (IPC)

3 Aug

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

Life Science Nation (LSN)’s next event, RESI September, is coming up on September 18. The conference will take place at the Boston Park Plaza, located in the heart of Boston – a hub of life science and healthcare innovation.

RESI has consistently provided an exceptional opportunity for entrepreneurs to pitch directly to a panel of active investors and industry experts through the Innovator’s Pitch Challenge (IPC). The IPC has rapidly gained popularity and has become the go-to event for many successful entrepreneurs to fine-tune their pitching skills, receive valuable feedback on their products and technologies and connect directly with seasoned investors.

During an IPC session, participating companies will be given 4 minutes for their presentation, followed by 9 minutes of Q&A. IPC’s unique format and judge recruitment process allows companies to pitch alongside fellow entrepreneurs operating in the same sectors and in front of a panel of investor pitch judges who are immensely experienced in that particular sector. By joining the IPC, companies gain not only significant exposure, but also invaluable connections with influential investors and industry experts.

We are excited to announce a selection of the confirmed companies that will be pitching at RESI September. Don’t forget to submit your application before the deadline on August 9 to join these companies at RESI September IPC.

Confirmed Pitch Companies
And More…

RESI-Boston-2023-September-1100px-w

← Older Entries
Newer Entries →